Clinical Trial Update: Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating talimogene laherparepvec in combination with pembrolizumab for recurrent metastatic squamous cell carcinoma of the head and neck has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Talimogene laherparepvec (talimogene laherparepvec)

Snippet

Sponsor: Amgen | Conditions: Carcinoma of the Head and Neck | Phase 1 | Status: COMPLETED | Results posted: 2019-06-10